Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherko Kuemmel

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 6, 2009
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patientsTill A Heusner, Sherko Kuemmel, Steffen Hahn, et al.
Anticancer Research|April 1, 2009
Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancerSherko Kuemmel, Anke Thomas, Solveig Landt, et al.
Anticancer Research|March 25, 2010
Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancerSolveig Landt, Sophia Jeschke, Angela Koeninger, et al.
The Oncologist|June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert PanelBolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|July 5, 2012
FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial resultsChristian Buchbender, Sherko Kuemmel, Oliver Hoffmann, et al.
Academic Radiology|July 6, 2010
Dynamic contrast-enhanced breast MRI at 7 Tesla utilizing a single-loop coil: a feasibility trialLale Umutlu, Stefan Maderwald, Oliver Kraff, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2025
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trialsLowell L Hart, Seock-Ah Im, Sara M Tolaney, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 16, 2022
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancerIsabel Grote, Stephan Bartels, Henriette Christgen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2022
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerSandra M Swain, Antoinette R Tan, Luca Gianni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 13, 2019
Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trialBeyhan Ataseven, Johanna Frindte, Philipp Harter, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Nuclear Medicine and Molecular Imaging|May 6, 2009
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patientsTill A Heusner, Sherko Kuemmel, Steffen Hahn, et al.
Anticancer Research|April 1, 2009
Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancerSherko Kuemmel, Anke Thomas, Solveig Landt, et al.
Anticancer Research|March 25, 2010
Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancerSolveig Landt, Sophia Jeschke, Angela Koeninger, et al.
The Oncologist|June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert PanelBolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|July 5, 2012
FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial resultsChristian Buchbender, Sherko Kuemmel, Oliver Hoffmann, et al.
Academic Radiology|July 6, 2010
Dynamic contrast-enhanced breast MRI at 7 Tesla utilizing a single-loop coil: a feasibility trialLale Umutlu, Stefan Maderwald, Oliver Kraff, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2025
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trialsLowell L Hart, Seock-Ah Im, Sara M Tolaney, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 16, 2022
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancerIsabel Grote, Stephan Bartels, Henriette Christgen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2022
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancerSandra M Swain, Antoinette R Tan, Luca Gianni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 13, 2019
Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trialBeyhan Ataseven, Johanna Frindte, Philipp Harter, et al.
Pageof 9